Back to top
more

Compugen (CGEN)

(Real Time Quote from BATS)

$1.74 USD

1.74
112,829

+0.11 (6.75%)

Updated Aug 8, 2024 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of 75% and 150.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Alterity (ATHE) Up on Interim Data From Advance MSA Study

by Zacks Equity Research

Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

by Zacks Equity Research

Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

by Zacks Equity Research

Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.

Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why

by Zacks Equity Research

Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.

Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan

by Zacks Equity Research

Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

by Zacks Equity Research

Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.

United Therapeutics (UTHR) Completes Enrolment in IPF Study

by Zacks Equity Research

United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

by Zacks Equity Research

Indivior (INDV) slashes financial guidance for 2024, primarily to reflect adverse sales conditions of its top-selling opioid drug. It will discontinue the sales of its schizophrenia drug.

uniQure (QURE) Soars on New Huntington's Disease Study Data

by Zacks Equity Research

uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

by Zacks Equity Research

IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

by Zacks Equity Research

Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why

by Zacks Equity Research

Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

by Zacks Equity Research

The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.

Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe

by Zacks Equity Research

Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

by Zacks Equity Research

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

by Zacks Equity Research

Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

by Zacks Equity Research

Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

by Zacks Equity Research

Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

by Zacks Equity Research

Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.

Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting

by Zacks Equity Research

Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

by Zacks Equity Research

Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.

Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal

by Zacks Equity Research

Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.

CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business

by Zacks Equity Research

CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.